Every AI express, investors ask questions on the investor interaction platform: what is the current capacity of the company to treat covid-19?
Jilin Aodong Pharmaceutical Group Co.Ltd(000623) ( Jilin Aodong Pharmaceutical Group Co.Ltd(000623) . SZ) said on the investor interaction platform on April 2 that after the urgent investigation of the covid-19 pneumonia epidemic prevention and control leading group in Jilin Province, the company’s subsidiary Jilin Aodong Pharmaceutical Group Co.Ltd(000623) Yanbian Pharmaceutical Co., Ltd. is one of the two enterprises with sufficient drug raw materials and batch processing capacity; The subsidiary Jilin Aodong Pharmaceutical Group Co.Ltd(000623) Shihang Pharmaceutical Co., Ltd. can carry out order processing in the way of market-oriented supply guarantee. As of March 30, 2022, according to the requirements of the leading group of New Coronavirus, pneumonia, epidemic prevention and control at the provincial, state and municipal levels, the subsidiary company has provided about 1 million 210 thousand products of Chinese medicine decoction and granules, and the following companies will do a good job in product supply according to the epidemic prevention needs. At present, the company can produce 550000 sets of traditional Chinese medicine epidemic prevention prescriptions and 100000 sets of tea drinks every day.
